Virus Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Virus Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bird Flu
HepaLife's Patented ''PBS-1'' Cells for Avian Flu Vaccines Outperform Current Cell System by 500%
April 10th, 2007
HepaLife Technologies, Inc. (OTCBB:HPLF) (FWB:HL1) (WKN:500625) announced that the Company's patented "PBS-1" cells, under development for influenza vaccine production, have successfully replicated numerous human influenza virus strains received from the Centers for Disease Control (CDC) at substantially higher levels than the research community's widely used current model, primary chick kidney cells. "The single most important step towards the production of a cell-culture-based vaccine against a targeted virus is the ability to grow the same virus in a cell substrate. The announcement clearly demonstrates that not only are HepaLife's PBS-1 cells capable of replicating...
Source: Virus Weekly (2007-04-10)
|
